RxDoctor Payments Data

Soraj Arora, DO

Internal Medicine · Munster, INNPI 1871571208

Payments from drug & device makers

$8,993in general payments, 2019–2025

Across 576 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Vanda Pharmaceuticals Inc.$804
  • AbbVie$773
  • AstraZeneca$771
  • Nestle Healthcare Nutrition Inc.$759
  • Novo Nordisk$753
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,993 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$701,772
Medicare patients
507
Services billed
6,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon13$304,191
MounjaroTirzepatide70$90,281
EliquisApixaban150$68,007
OzempicSemaglutide57$64,074
FarxigaDapagliflozin Propanediol43$55,682
Repatha SureclickEvolocumab40$32,877
TradjentaLinagliptin24$25,210
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$23,283
LinzessLinaclotide19$21,805
VascepaIcosapent Ethyl21$16,014
EntrestoSacubitril/Valsartan35$14,058
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$12,519
Xultophy 100-3.6Insulin Degludec/Liraglutide12$10,386
TrulicityDulaglutide36$9,381
XareltoRivaroxaban29$9,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$804$304,19113 claims
Lilly USA, LLCMounjaro, Trulicity$272$99,662106 claims
Novo NordiskOzempic, Xultophy 100-3.6$753$74,46069 claims
AstraZenecaFarxiga, Breztri Aerosphere$771$68,20055 claims
PfizerEliquis$76$68,007150 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$127$36,58854 claims
Boehringer IngelheimTradjenta$12$25,21024 claims
AbbVieLinzess$773$21,80519 claims
Johnson & JohnsonXarelto$222$9,35529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →